OptimizeRx Corp 8-K

What Happened

• OptimizeRx Corporation (OPRX) filed an 8-K reporting results from its June 9, 2026 Annual Meeting of Shareholders. Shareholders approved Amendment No. 2 to the company’s 2021 Equity Incentive Plan to increase the number of shares available for awards by 1,000,000 shares, raising the total to 5,450,000 shares. The amendment is attached as Exhibit 10.1 to the filing.
• At the meeting shareholders elected all seven director nominees to serve until the next annual meeting, approved (on an advisory basis) the compensation of the company’s named executive officers, rejected an evergreen amendment to the Equity Plan, and ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal 2026.

Key Details

• Record date and voting population: 18,765,075 shares outstanding and entitled to vote as of April 10, 2026.
• Equity Plan increase (Amendment No. 2): Approved — Votes For: 11,541,123; Against: 1,096,197; Abstain: 16,476; Broker Non-Votes: 3,138,456. New authorized shares under the plan: 5,450,000.
• Evergreen amendment to the Equity Plan: Not approved — Votes For: 5,627,324; Against: 7,001,699; Abstain: 24,773; Broker Non-Votes: 3,138,456.
• Director elections and auditor ratification: All seven nominees elected (votes for nominees ranged from 8,327,850 to 12,160,558). Grant Thornton LLP ratified as auditor — Votes For: 15,750,329; Against: 27,585; Abstain: 14,338.

Why It Matters

• The approved 1,000,000-share increase gives OptimizeRx more shares to grant as equity awards (for employees, directors and executives), which can help attract and retain talent but may increase potential dilution for existing shareholders.
• The advisory approval of executive compensation signals shareholder support for pay practices, while rejection of the evergreen amendment shows shareholders were not willing to authorize automatic annual increases to the plan.
• Ratification of the auditor provides continuity for the company’s 2026 financial reporting. Investors should watch future disclosures for any equity award activity and potential dilution from grants under the expanded plan.